Expanding at 5.20% CAGR between 2020 and 2027, North America Liver Disease Treatment Market to touch US$8.31 Billion by 2027

Posted on
by

Expanding at 5.20% CAGR between 2020 and 2027, North America Liver Disease Treatment Market to touch US$8.31 Billion by 2027
NORTH AMERICA LIVER DISEASE TREATMENT MARKET BY TREATMENT TYPE (ANTIVIRAL DRUGS, IMMUNOSUPPRESSANTS, VACCINES, IMMUNOGLOBULINS, CORTICOSTEROIDS, TARGETED THERAPY, AND CHEMOTHERAPY) AND DISEASE TYPE (HEPATITIS, AUTOIMMUNE DISEASES, NON-ALCOHOLIC FATTY LIVER DISEASE, CANCER, GENETIC DISORDERS, AND OTHERS): OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST, 2020-2027

Report Ocean has recently published a research study on the North America liver disease treatment market. The report, titled “North America Liver Disease Treatment Market by Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, and Chemotherapy) and Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others): Opportunity Analysis and Industry Forecast, 2020–2027,” offers a detailed assessment of this market, including individual analyses of each of its segments.

 GET SAMPLE COPY @ https://reportocean.com/industry-verticals/sample-request?report_id=AMR1252

The North America liver disease treatment market accounted for US$6.97 bn in 2019. Progressing at a CAGR of 5.20% during the period from 2020 to 2027 and reach US$8.31 bn by the end of the forecast period. The increasing alcohol consumption and drug abuse is giving rise to the number of patients suffering from liver diseases in North America. This, in turn, is fueling the demand for liver disease treatment significantly in this region. Furthermore, several factors, such as surge in the geriatric population and the rise in government and non-government awareness programs are also propelling this market.

On the other hand, stringent approval process in relation with drugs and resistance to antiviral drugs utilized in treatment of hepatitis B and hepatitis C may limit the growth of the North America liver disease treatment market over the next few years. The humongous capital investments required for approval processes are also a negative sign for this market. Also, any new drug maker that tries to enter this market is bound to abide by these regulations. The time consuming procedures, extending the time for approval and commercialization, are likely to hinder the market in the years to come. Nonetheless, the presence of strong pipeline products may offer lucrative opportunities for players in the long run.

Impact of Covid 19 on North America Liver Disease Treatment Market

The Coronavirus pandemic has shifted everyone’s focus towards Covid 19 and pushed other things in the corner. The North America liver disease treatment market is also affected by the emergence of this virus. The investments in research for the development of these services have now found their route towards research for Covid Vaccines and treatments. Researchers expect this scenario to remain so over the next few months.

In this report, the North America liver disease treatment market has been analyzed on the basis of the treatment type, disease type, and the country to provide a detailed assessment of the market. Based on the type of the treatment, the market has been classified into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Based on the disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others. On the basis of the country, it is classified into the U.S., Canada, and Mexico.

The key players in the North America liver disease treatment market, profiled in this report, are Astellas Pharma Inc., Mylan N.V., AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Eli Lilly and Company, Pfizer Inc., Dynavax Technologies, Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).

Key Findings:

  • The increasing alcohol consumption and drug abuse is giving rise to the number of patients suffering from liver diseases in North America.
  • Stringent approval process in relation with drugs and resistance to antiviral drugs utilized in treatment of hepatitis B and hepatitis C may limit the growth of the North America liver disease treatment market over the next few years.

The North America liver disease treatment market is classified into:

By Treatment Type

  • Antiviral Drugs
  • Immunosuppressants
  • Vaccines
  • Immunoglobulins
  • Corticosteroids
  • Targeted Therapy
  • Chemotherapy

By Disease Type

  • Hepatits
  • Autoimmune Diseases
  • Ischemic Stroke
  • Stenosis
  • Others

By Country

  • U.S.
  • Canada
  • Mexico

Companies Mentioned in the Report

  • Astellas Pharma Inc.
  • Mylan
  • AbbVie Inc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Eli Lilly and Company
  • Dynavax Technologies
  • Pfizer Inc.
  • Gilead Sciences, Inc.,
  • Bristol Myers Squibb
  • Emergent BioSolutions (Cangene bioPharma)

READ FULL REPORT @ https://reportocean.com/industry-verticals/sample-request?report_id=AMR1252

Media Contact
Company Name: Report Ocean
Contact Person: Nishi Sharma
Email: Send Email
Phone: +91-9997112116
Address:BSI Business Park,H-15, Sector-63, Noida
City: Noida
State: UP, 201301
Country: India
Website: www.reportocean.com